The Panel provides updated information on the use of abatacept, infliximab, remdesivir, sarilumab, and tofacitinib to treat certain hospitalized adults with COVID-19.
A new section discusses the available clinical data on the use of abatacept, a soluble fusion protein that is used to block T cell activation, to treat certain hospitalized patients with COVID-19.
A new section discusses the available clinical data on the use of infliximab, a TNF-alpha inhibitor, to treat certain hospitalized patients with COVID-19.
The Panel provides updated information on the use of abatacept, infliximab, remdesivir, sarilumab, and tofacitinib to treat certain hospitalized adults with COVID-19.
A new section discusses the available clinical data on the use of abatacept, a soluble fusion protein that is used to block T cell activation, to treat certain hospitalized patients with COVID-19.
A new section discusses the available clinical data on the use of infliximab, a TNF-alpha inhibitor, to treat certain hospitalized patients with COVID-19.
The Panel provides updated information on the use of abatacept, infliximab, remdesivir, sarilumab, and tofacitinib to treat certain hospitalized adults with COVID-19.
A new section discusses the available clinical data on the use of abatacept, a soluble fusion protein that is used to block T cell activation, to treat certain hospitalized patients with COVID-19.
A new section discusses the available clinical data on the use of infliximab, a TNF-alpha inhibitor, to treat certain hospitalized patients with COVID-19.